Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon‐like peptide‐1 receptor agonists or sodium‐glucose cotransporter‐2 inhibitors: A real‐world study in two Italian cohorts
Marta Baviera, Stefano Genovese, Vito Lepore, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. 7, pp. 1484-1495
Closed Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

Efficacy of cardiometabolic drugs in reduction of epicardial adipose tissue: a systematic review and meta-analysis
Veronika A. Myasoedova, Valentina Parisi, Donato Moschetta, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 43
Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Studies
Irene Caruso, Angelo Cignarelli, Gian Pio Sorice, et al.
Metabolites (2022) Vol. 12, Iss. 2, pp. 183-183
Open Access | Times Cited: 63
Liraglutide for Lower Limb Perfusion in People With Type 2 Diabetes and Peripheral Artery Disease
Paola Caruso, Maria Ida Maiorino, Miriam Longo, et al.
JAMA Network Open (2024) Vol. 7, Iss. 3, pp. e241545-e241545
Open Access | Times Cited: 12
Cardiovascular Protective Properties of GLP-1 Receptor Agonists: More than Just Diabetic and Weight Loss Drugs
Richard Le, Mau T. Nguyen, Momina A. Allahwala, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 16, pp. 4674-4674
Open Access | Times Cited: 11
SGLT-2 inhibitors as cardio-renal protective agents
Irene Caruso, Francesco Giorgino
Metabolism (2021) Vol. 127, pp. 154937-154937
Closed Access | Times Cited: 41
Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study
Marta Baviera, Andreana Foresta, Pierluca Colacioppo, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 29
Effect of Glucagon-like Peptide-1 Receptor Agonists on Prognosis of Heart Failure and Cardiac Function: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Huixing Liu, Di Fu, Daoquan Peng
Clinical Therapeutics (2023) Vol. 45, Iss. 1, pp. 17-30
Open Access | Times Cited: 18
Cardiorenal Impact of SGLT-2 Inhibitors: A Conceptual Revolution in The Management of Type 2 Diabetes, Heart Failure and Chronic Kidney Disease
Riccardo Nevola, Maria Rosaria Alfano, Pia Clara Pafundi, et al.
Reviews in Cardiovascular Medicine (2022) Vol. 23, Iss. 3
Open Access | Times Cited: 25
GLP-1RAs for Ischemic Stroke Prevention in Patients With Type 2 Diabetes Without Established Atherosclerotic Cardiovascular Disease
Yi‐Sun Yang, Hsin‐Hung Chen, Chien‐Ning Huang, et al.
Diabetes Care (2022) Vol. 45, Iss. 5, pp. 1184-1192
Open Access | Times Cited: 21
Incretins and cardiovascular disease: to the heart of type 2 diabetes?
Anna Solini, Domenico Tricò, Stefano Del Prato
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1820-1831
Open Access | Times Cited: 12
Effect of glucagon-like peptide-1 receptor agonists on the risk of major adverse limb events in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized clinical trials
Fernando Garagoli, Walter Masson, Leandro Barbagelata, et al.
Endocrinología Diabetes y Nutrición (2025), pp. 501562-501562
Closed Access
Effects of SGLT2 inhibitors and GLP1-receptor agonists on cardiovascular and limb events in peripheral artery disease: A review
Nedaa Skeik, Sewar A. Elejla, Anish Sethi, et al.
Vascular Medicine (2023) Vol. 28, Iss. 1, pp. 62-76
Closed Access | Times Cited: 10
Peripheral Artery Disease
Matthew Bierowski, Taki Galanis, Amry Majeed, et al.
Medical Clinics of North America (2023) Vol. 107, Iss. 5, pp. 807-822
Closed Access | Times Cited: 9
Prevalence of sodium-glucose transporter 2 inhibitor-associated diabetic ketoacidosis in real-world data: A systematic review and meta-analysis
Bassel Al-Hindi, Mohammed A. Mohammed, Ernest Mangantig, et al.
Journal of the American Pharmacists Association (2023) Vol. 64, Iss. 1, pp. 9-26.e6
Closed Access | Times Cited: 9
Impact of Glucagon-like peptide 1 receptor agonists on peripheral arterial disease in people with diabetes mellitus: A narrative review
Alexandros L. Liarakos, Anastasios Tentolouris, Alexandros Kokkinos, et al.
Journal of Diabetes and its Complications (2022) Vol. 37, Iss. 2, pp. 108390-108390
Closed Access | Times Cited: 15
Insulin treatment in patients with diabetes mellitus and heart failure in the era of new antidiabetic medications
Lidia Staszewsky, Marta Baviera, Mauro Tettamanti, et al.
BMJ Open Diabetes Research & Care (2022) Vol. 10, Iss. 2, pp. e002708-e002708
Open Access | Times Cited: 11
SGLT2 inhibitors reduce epicardial adipose tissue more than GLP‐1 agonists or exercise interventions in patients with type 2 diabetes mellitus and/or obesity: A systematic review and network meta‐analysis
Yu Bao, Yucai Hu, Menglong Shi, et al.
Diabetes Obesity and Metabolism (2024)
Closed Access | Times Cited: 2
Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Cardiovascular Disease: The Past, Present, and Future
Filipe Ferrari, Rafael Selbach Scheffel, Vítor Magnus Martins, et al.
American Journal of Cardiovascular Drugs (2021) Vol. 22, Iss. 4, pp. 363-383
Closed Access | Times Cited: 13
Sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes: Are clinical trial benefits for heart failure reflected in real‐world clinical practice? A systematic review and meta‐analysis of observational studies
William Hinton, Abdus Samad Ansari, Martin Whyte, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 2, pp. 501-515
Closed Access | Times Cited: 9
Effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and cerebrovascular diseases: a meta-analysis of controlled clinical trials
Fei Wang, Chunyu Li, Lili Cui, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 1
Current gaps in management and timely referral of cardiorenal complications among people with type 2 diabetes mellitus in the Middle East and African countries: Expert recommendations
Alper Sönmez, Hani Sabbour, Akram Echtay, et al.
Journal of Diabetes (2022) Vol. 14, Iss. 5, pp. 315-333
Open Access | Times Cited: 7
Management of type 2 diabetes with a treat-to-benefit approach improved long-term cardiovascular outcomes under routine care
Mario Luca Morieri, Enrico Longato, Barbara Di Camillo, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 4
Long-Term Cardiovascular Outcomes of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Type 2 Diabetes: A Systematic Review
Salman Tariq, M. Ali, Haris Iftikhar, et al.
Cureus (2024)
Open Access
Evaluation of the Safety and Tolerability of Sodium-Glucose Co-transporter 2 Inhibitors in the Older Population: A Systematic Review
Sarah Edwards, Christine Lam, Lindsey J. Thomas
The Senior Care Pharmacist (2023) Vol. 38, Iss. 7, pp. 276-287
Closed Access | Times Cited: 1
The Impact of COPD on Hospitalized Patients with Diabetes: A Propensity Score Matched Analysis on Discharge Records
Giuseppe Di Martino, Pamela Di Giovanni, Fabrizio Cedrone, et al.
Healthcare (2022) Vol. 10, Iss. 5, pp. 885-885
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top